secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zymeworks Inc. (ZYME)
CIK:        0001937653
Form:       8-K
Filed at:   2026-04-01T23:59:59+00:00
Accession:  0001193125-26-135610
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zymeworks appoints Kristin Stafford as CFO, effective April 1, 2026
-------------------------------------------------------------------

- Stafford previously SVP, CAO at Royalty Pharma; brings life sciences capital markets experience.
- Compensation includes $520K annual base salary, 45% target bonus, $52K signing bonus.
- Equity awards: 178K options, 119K RSUs (4-year vest), and 50K RSUs (3-year vest).
- Kenneth Galbraith ceases as interim CFO but remains CEO and Chairman of the Board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937653/000119312526135610/0001193125-26-135610-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937653/000119312526135610/d142598d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-135610

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer